DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at Stifel’s Third Annual CNS Day, which is being held on March 31st.
Avadel’s fireside chat is scheduled for 3 p.m. ET on Wednesday, March 31st. A live webcast of this event, as well as an archived recording, will be available at (click here), as well as on Avadel’s website, www.avadel.com, for 90 days from being made available.
Contacts:
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com
Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915-2564
Email: tim@lifesciadvisors.com
Shrivers Hospice sets a benchmark for quality care in Ohio with prestigious award LOS ANGELES,…
Renowned Home care service provider honored with prestigious award by The Wound Pros LOS ANGELES,…
Seasoned medical professional brings over a decade of expertise to The Wound Pros LOS ANGELES,…
NEW YORK, June 21, 2024 /PRNewswire/ -- The global medical facility environmental monitoring system market…
MARIETTA, Ga., June 21, 2024 /PRNewswire/ -- Pinnacle Orthopaedics & Sports Medicine Specialists LLC ("Pinnacle")…
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the…